Insight Molecular Diagnostics
IMDX
52 hedge funds and large institutions have $19.7M invested in Insight Molecular Diagnostics in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 19 reducing their positions, and 7 closing their positions.
1% more capital invested
Capital invested by funds: $19.6M → $19.7M (+$140K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.22% less ownership
Funds ownership: 2.56% → 2.35% (-0.22%)
10% less funds holding
Funds holding: 58 → 52 (-6)
74% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 19
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Defender Capital
Charlotte,
North Carolina
|
+$33.6K |
| 2 |
Renaissance Technologies
New York
|
+$11.7K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.9K |
| 4 |
BlackRock
New York
|
+$2.59K |
| 5 |
LPL Financial
San Diego,
California
|
+$2.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$1.44M |
| 2 |
AIC
AWM Investment Company
New York
|
-$179K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$149K |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
-$98K |
| 5 |
E
Ergoteles
New York
|
-$33K |
IMDX Hedge Fund Activity: Q1 2023 in Review
52 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q1 2023, worth a combined $19.7M — up 0.72% from $19.6M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of IMDX and 1 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 5 added.
The largest buyer was Defender Capital, adding an estimated $33.6K. The largest seller was Pura Vida Investments, cutting an estimated $1.44M.
- 52 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q1 2023, down from 58 in Q4 2022.
- Funds reported $19.7M of Insight Molecular Diagnostics stock for Q1 2023, up 0.72% quarter-over-quarter.
- 1 fund opened new Insight Molecular Diagnostics positions in Q1 2023 and 7 closed out, a net change of -6 holders.
- The largest Insight Molecular Diagnostics buyer in Q1 2023 was Defender Capital, an estimated $33.6K added.
- The largest Insight Molecular Diagnostics seller in Q1 2023 was Pura Vida Investments, an estimated $1.44M sold.
Based on aggregated 13F filings for Q1 2023.